Table 1

Number of study sites and patients and selected baseline patient level factors of each country* participating in the GUSTO IV ACS trial

Country	Sites (n)	Patients (n)	Median age	Female (%)	Prior MI (%)	Diabetes (%)	TnT(%)	ST depression(%)	Creatinine clearance (%)	CRP (%)	Enrolment MI (%)
*The actual number of sites from 458 possible sites that had enrolled at least one patient. CRP, C reactive protein >1110 mg/l; creatinine clearance<58.4 ml/min; MI, myocardial infarction; ST segment depression ⩾1mm; TnT, troponin T >0.01 μg/l. All missing data were imputed as positive for these indicators.
North America
Canada	31	642	65	31	34	25	46	28	79	59	36
United States	48	462	66	42	33	33	39	36	71	68	34
Western Europe
Austria	8	78	66	33	30	35	81	32	66	36	13
Belgium	9	163	66	33	31	21	74	43	73	24	36
France	15	197	68	27	26	17	71	29	67	24	25
Germany	32	395	68	34	26	25	75	42	75	29	28
Greece	15	259	66	35	26	31	66	49	73	24	20
Ireland	5	40	64	15	40	10	83	23	78	43	23
Italy	29	486	66	34	30	21	76	42	71	27	27
Netherlands	27	570	66	33	26	11	71	43	83	25	31
Portugal	8	88	68	25	23	19	83	38	75	25	36
Spain	11	362	68	29	20	23	74	40	75	29	40
Switzerland	7	38	65	32	29	11	82	43	76	34	34
UK	15	124	64	30	36	16	77	32	76	29	35
Scandinavia
Denmark	12	149	66	28	29	10	80	38	80	35	31
Finland	2	79	66	32	34	18	80	42	79	22	28
Norway	10	91	64	42	23	21	84	26	78	23	31
Sweden	28	544	70	34	31	16	88	31	73	22	33
Eastern Europe
Czech	16	765	69	49	38	31	71	51	66	26	29
Poland	24	1657	65	49	34	17	50	44	81	19	26
Other
Australia	9	118	66	35	27	14	64	40	64	40	40
Israel	13	265	63	26	35	30	78	39	76	34	27
New Zealand	3	54	61	20	33	13	94	26	80	24	43
South Africa	10	144	60	22	17	19	76	34	80	33	41
All countries	387	7800	66	38	31	22	66	40	75	31	28